CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO
December 20 2021 - 08:30AM
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand, and
treat rare diseases, announced today that its Chief Executive
Officer, Andrin Oswald, M.D., is taking a temporary medical leave
of absence for a period of at least four weeks.
The accomplished biopharmaceutical industry executive Kim
Stratton has been appointed as the Interim Chief Executive Officer
of the Company during this time.
"The Board wishes Andrin a quick recovery as he focuses on his
health." said Peer Schatz, Chairman of the Supervisory Board of
CENTOGENE. "We have full confidence in the excellent management
team that Andrin has built. We are also very pleased to have been
able to secure the support of Kim Stratton to join us as Interim
CEO. Kim is an outstanding leader with a great track record in rare
diseases, and who has known and interacted with the Company for
many years. With her support, our strong leadership team, and our
committed and talented employees, we are well equipped to continue
to drive the Company's new strategy and its ongoing transformation
while managing day-to-day operations during Andrin’s absence."
Kim Stratton has more than 25 years’ global commercial expertise
in the biopharmaceutical space, with significant experience across
multiple geographies, including the U.K., U.S., Europe, and
emerging markets. Most recently, Stratton was CEO of Orphazyme A/S
(ORPHA.CO), a biopharmaceutical company dedicated to developing
treatments for patients living with rare diseases. Prior to this
role, Stratton worked at Shire Pharmaceuticals, where she served as
Head International Commercial for Shire’s Specialty and Rare
Diseases portfolio. Before Shire, Stratton spent nearly 15 years at
Novartis in a number of senior management roles, including global
product development, commercial, marketing, general manager, and
various global corporate functions, including government and
external affairs. Stratton also currently serves as a non-executive
director on the Boards of Recordati S.p.A, Novozymes A/S, and Vifor
Pharma AG.
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 600,000 patients representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Follow us on LinkedIn
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative worldwide economic conditions and ongoing instability and
volatility in the worldwide financial markets, the effects of the
COVID-19 pandemic on our business and results of operations,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our requirement for
additional financing and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media
Contact: CENTOGENE Ben
Legg Corporate
Communications Ben.Legg@centogene.com
Lennart Streibel Investor
Relations Investor.Relations@centogene.com Stern
IR Brendan Payne+1 (212) 698
8695brendan.payne@sternir.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2023 to Mar 2024